SynthesisObesity surgery2026
Long-Term Outcomes of One-Anastomosis Gastric Bypass: A Systematic Review of Studies with at Least 10 Years of Follow-Up.
Synthesis in Obesity surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Outcomes and Recurrent Weight Gain 10 Years After Roux-en-Y Gastric Bypass, a Longitudinal Cohort Study.Obesity surgery · 2026Article
- Management of Recurrent Weight Gain After Sleeve Gastrectomy: Comparative Effectiveness of Conversion Procedures Versus Obesity Management Medications.Obesity surgery · 2026Article
- Laparoscopic Sleeve Gastrectomy Versus One-Anastomosis Gastric Bypass and the Risk of De Novo or Persistent Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One anastomosis gastric bypass (OAGB) is increasingly becoming popular worldwide and is considered a safe and effective procedure. However, data regarding long-term efficacy is lacking. We performed a systematic review of articles reporting outcomes in patients with a minimum follow-up of 10 years. Five retrospective studies comprising 1,750 patients met the inclusion criteria. Overall, the weighted mean percentage of total weight loss was 31.1% ( range 29.6-32.1), and remission rates of type 2 diabetes and hypertension ranged from 70.8 to 90% and 56.7-85%, respectively. Conversion or revisional surgery following OAGB was required in 5.2% ( range 3.3-6.4%) of patients on average. This systematic review suggests that OAGB remains a relatively effective and safe procedure after 10 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.